Pharmaceutical and diagnostics companies are adamantly opposed to the U.S. Patent and Trademark Office’s guidance for determining the patent eligibility of products derived from natural sources, saying it will deter development of many new therapies and tests.
The PTO issued the guidance in March to implement a new procedure for evaluating patent claims involving laws...